Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

A vizsgálat adatai

Ki végzi

Stryker Neurovascular

Azonosító

NCT06872684

A regiszteradat frissítve

2026. október 21.

Eredeti leírás

The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.A teljes eredeti leírásKevesebb

Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter

The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.

Bevonási feltételek: Age is ≥18 and ≤80 years at the time of consent; Has a single unruptured target intracranial aneurysm (IA) of any size with the following characteristics:; Is located on the internal carotid artery or its branches; Has a wide neck (wide neck typically defined as neck width ≥ 4 millimeter (mm), or dome to neck ratio ≤ 2.0) or no discernible neck; Aneurysm is either saccular or fusiform in nature; Has a parent vessel diameter ≥ 3.0 mm to ≤ 6.0 mm at the largest diameter; There is documented risk-benefit of endovascular treatment that outweighs the risks of intracranial aneurysm rupture during the subject's expected lifetime if left untreated.

Kizáró feltételek: Received previous treatment for the target aneurysm or parent artery where it would interfere with the placement or proper apposition of the device; Patients with heparin hypersensitivity, including patients with a previous incident of Heparin-Induced Thrombocytopenia (HIT); Presence of unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days prior to the index procedure); Subarachnoid hemorrhage occurred within 30 days prior to the index procedure; Major surgery (including previous intracranial implant) either occurred within 30 days prior to the index procedure date or is planned to occur within 120 days following the index procedure date; Received previous intracranial implant associated with the symptomatic or vascular distribution within the past 84 days prior to treatment date; Chronic anticoagulation therapy is ongoing or known coagulopathy exists; Enrollment in another study involving an investigational product that could confound the outcomes of this trial; Has a medical contraindication to trial or procedure related antiplatelet medications (aspirin, clopidogrel/Plavix, ticagrelor, and heparin), local or general anesthesia, or life-threatening allergy to contrast dye; Has a known severe allergy to nickel, chromium cobalt, tungsten, or platinum; Has acute life-threatening illness (e.g., acute kidney or heart failure) other than the neurological disease to be treated in this trial; Evidence of active infection at the time of treatment; Life expectancy is less than 5 years due to other illness or condition (in addition to an intracranial aneurysm); Unable to comply with the trial follow up requirements due to conditions such as dementia or psychiatric problems, active substance abuse, or history of non-compliance with medical advice, as determined by the investigator; Presence of intracranial mass (tumor, except meningioma, abscess, or other infection), non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm; Has other known serious concurrent medical conditions such as cardiovascular disease (including recent myocardial infarction [<12 weeks], symptomatic congestive heart failure, or carotid stenosis), kidney failure (>2.0 mg/dl serum creatinine), pulmonary disease, uncontrolled diabetes, progressive neurologic disorders, terminal cancer, vasculitis, high risk of ischemic stroke or recent stroke; Has an extradural target aneurysm; Has a target aneurysm in the posterior circulation; Perforator or branch vessel, inclusive of the posterior communicating artery, arises from the target aneurysm body or neck (branches or arteries must arise or connect from the parent vessel separate from the aneurysm or neck to not be excluded from trial); Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at a point of vessel bifurcation; Has vessel characteristics, such as severe tortuosity (cavernous Internal Carotid Artery (cICA) Type IV1), stenosis (>70%), or morphology that would preclude safe endovascular access or proper deployment of the trial device to the target aneurysm; Modified Rankin Score (mRS) assessment is ≥ 3 at pre-procedure exam; Has more than one intracranial aneurysm (IA) that requires treatment within 12 months after the index procedure; Has atrial fibrillation with or without pacemaker; Pregnant or breast- feeding women or women who wish to become pregnant during the length of trial participation.

ClinicalTrials.gov NCT06872684